Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky
Bright Minds Biosciences (DRUG) shares sold off sharply as the market reacted to an FDA partial clinical hold on the planned Phase 2 BMB-101 pediatric epilepsy trial. An investigation into potential securities law violations is underway on behalf of investors who lost money. NEW YORK, Nov....